Drugs.com - Clinical Trials

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...

Mar 18, 2025 - 00:15
 0
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes
HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being...
Read More

Tags:

Previous Article

France : Un marché de la beauté atone tiré par les ventes en pharmacies

Next Article

BioArctic Receives Orphan Drug Designation for Exidavnemab the US

Related Posts

FDA Grants Fast Track Designation to PleoPharma, Inc's Investigational New Drug, PP-01, for the Mitigation of Cannabis Withdrawal Symptoms in Patients With Cannabis Use Disorder

FDA Grants Fast Track Designation to PleoPharma, Inc's ...

Feb 17, 2025  0

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy

Vertex Announces Results From Phase 2 Study of Suzetrig...

Feb 9, 2025  0

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics Provides Update on BEACON-IPF, a Ph...

Feb 10, 2025  0